NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.87 -0.04 (-0.05%) GOLD FUTURES
2,364.50 -2.00 (-0.08%) DOW
38,111.48 -330.06 (-0.86%) Bitcoin GBP
53,711.19 +570.55 (+1.07%)
Checkpoint Therapeutics, Inc. (CZTA.F)
| Previous close | 1.6200 |
| Open | 1.6560 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.6560 - 1.6560 |
| 52-week range | 1.2860 - 3.0380 |
| Volume | |
| Avg. volume | 114 |
| Market cap | 63.523M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4100 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference. A w
Simply Wall St.Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)
Checkpoint Therapeutics ( NASDAQ:CKPT ) First Quarter 2024 Results Key Financial Results Net loss: US$10.9m (loss...
- GlobeNewswire
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have worked closely with our third-party contract manufacturing organization (“CMO”) for cosibelimab to resolve
